The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC
January 26th 2019Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.
BMS Withdraws Application for Nivolumab/Ipilimumab in TMB-High NSCLC
January 24th 2019Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC
January 17th 2019Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.
FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC
January 17th 2019The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.
Dr. Subramanian on Ongoing Trials for Patients With Nonsquamous NSCLC
January 16th 2019Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses ongoing trials evaluating the use of immunotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC).
FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC
December 21st 2018The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.
Dr. Brahmer on Biomarkers for Immune Response in NSCLC
December 18th 2018Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.
FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC
December 5th 2018The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Expert Highlights Management of Immune-Related Toxicities With NSCLC Treatment
November 29th 2018Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.
Durvalumab Combo Misses OS Endpoint in Frontline Metastatic NSCLC
November 16th 2018The frontline combination of durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival compared to standard chemotherapy in patients with metastatic non–small cell lung cancer.
Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC
October 31st 2018D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.